Gates Package — page 512

In that you comment 1) the state of 2d discussion. 2eping flexible ry, this format yject Manager for Strategic Planning and Engagement in From: "Handley, Gray (NIH/NIAID) [E]" </O=NIH/OU=NIHEXCHANGE/CN=RECIPIENTS/CN=HANDLEYGR> To: "Eiss, Robert (NIH/FIC) [E]" @mail.nih.gov> Subject: RE: October 7 visit of Bill Gates Date: Fri, 27 Sep 2013 14:09:17 -0400 Importance: Normal As always...>Thanks. Can I call you? From: Eiss, Robert (NIH/FIC) [E] Sent: Thursday, September 26, 2013 10:37 PM To: Handley, Gray (NIH/NIAID) [E] Subject: Fw: October 7 visit of Bill Gates From: Collins, Francis (NIH/OD) [E] Sent: Thursday, September 26, 2013 10:17 PM Eastern Standard Time To: Auchincloss, Hugh (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Glass, Roger (NIH/FIC) [E]; Guttmacher, Alan (NIH/NICHD) [E]; Germino, Gregory (NIH/NIDDK) [E]; Pettigrew, Roderic (NIH/NIBIB) [E]; Somerman, Martha (NIH/NIDCR) [E]; Austin, Christopher (NIH/NCATS) [E]; Varmus, Harold (NIH/NCI) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Goosby, Eric @state.gov) @state.gov> Cc: Eiss, Robert (NIH/FIC) [E]; Wood, Gretchen (NIH/OD) [E] Subject: October 7 visit of Bill Gates Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached.